Selective reporting of pharmaceutical data leads major medical journals to change editorial policy
Tom Perry, MD T he publication in Fall 2000 of the CLASS and VIGOR trials in JAMA and the New England Journal of Medicine (respectively) provided strong evidence for the cyclooxygenase (COX)-2 hypothesis: that COX-2 selective NSAIDs confer a gastrointestinal (GI) safety advantage over predecessor NSAIDs such as ibuprofen, naproxen or diclofenac. 1, 2 The publicity resulting from these trials helped prolong a multibillion dollar boom 3 in North American sales of celecoxib (Celebrex) and rofecoxib (Vioxx), which are the first COX-2 agents licensed in the US and Canada. But more complete information recently submitted to the US Food and Drug Administration (FDA) has prompted an outcry that Celebrex manufacturer Pharmacia and prominent US clinical investigators did not present their trial data fairly.
On Aug. 5, 2001, the Washington Post published a story entitled, "Missing data on Celebrex: Full study altered picture of drug." 4 The article recounts JAMA's publication of the CLASS study, which concluded that celecoxib might confer a GI safety advantage over ibuprofen and diclofenac. Boston gastroenterologists Drs. David R. Lichtenstein and M. Michael Wolfe had written a cautiously favourable editorial about the study in the same issue of JAMA. 5 However, last February, when Dr. Wolfe was shown the full study as a member of the FDA Arthritis Advisory Committee, he saw that the complete trial data painted a different picture, and that celecoxib did not appear to offer a significant safety advantage over the older, less expensive medications.
"We were flabbergasted," said Dr. Wolfe, 4 after learning that what the authors had represented as a single 6-month trial was actually a combined analysis of the first 6 months of 2 separate 12-month trials. The authors had omitted the second 6-month data set, in which the apparent celecoxib advantage melted away. JAMA Editor Catherine D. DeAngelis said the journal was not informed about the missing data. "I am disheartened to hear that they had those data at the time that they submitted to us. We are functioning on a level of trust that was, perhaps, broken." 4 This and similar incidents, plus the fact that research is now funded to a very large extent by pharmaceutical firms who have vested financial interests in the results, prompted the 11 editors of the Vancouver Group (International Committee of Medical Journal Editors) to issue new requirements for acceptance for publication of research funded by industry sponsors. 6 The requirements permit journal editors to review protocols and research contracts between the companies and investigators. Contracts that inhibit the full freedom of researchers to conduct the studies as they see fit and publish when they want may not be published.
University of British Columbia clinical pharmacologist Dr. James Wright is cited in the Washington Post article for having alerted JAMA to the misreporting of the CLASS trial data. Wright and colleagues at the UBC Therapeutics Initiative (www.ti.ubc.ca) submitted a letter to JAMA in July 2001 suggesting that the complete data from the CLASS trial indicate that celecoxib may cause more serious adverse events than ibuprofen or diclofenac (Dr. J. Wright, UBC Therapeutics Initiative, Vancouver: personal communication, 2001).
In its Aug. 22/29, 2001, issue, 3 JAMA published a Cleveland Clinic meta-analysis of the CLASS and VIGOR trials, 2 smaller unpublished robecoxib trials, and the full trial data submitted to the FDA, focussing on the risk of cardiovascular events associated with selective COX-2 inhibitors. This post-hoc analysis suggests that both rofecoxib and celecoxib may increase the risk of thrombotic cardiovascular events, including myocardial infaction, unstable angina, sudden death and ischemic stroke, when compared with other NSAIDs or with placebo. Rofecoxib was also associated with more frequent hypertension in the VIGOR trial, with mean blood pressure increases (systolic, 4.6 mm Hg; diastolic, 1.7 mm Hg) comparable but opposite to the mean effect of ramipril in the HOPE 7 trial. Equivalent data were not available from the CLASS study. Pending clarification from a prospective trial specifically assessing cardiovascular effects of COX-2 selective NSAIDs, the authors suggest "we urge caution in prescribing these agents to patients at risk for cardiovascular morbidity."
